Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

Tamashiro, Tamaki; Takada, Koji; Itagaki, Kanako; Nakayama, Makiko; Maruko, Ichiro; Wakugawa, Sorako; Terao, Nobuhiro; Onoe, Hajime; Wakatsuki, Yu; Ogasawara, M.; Sugano, Yukinori; Yamamoto, Akiko; Kataoka, Keiko; Izumi, Takahiko; Kawai, Moeko; Mori, Ryusaburo; Sekiryu, Tetsuju; Okada, Annabelle A.; Iida, Tomohiro; Koizumi, Hideki

doi:10.1007/s00417-021-05517-1

Cited by 26 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The loading dose of IVBr caused choroidal thinning with a 16% reduction in the original thickness, which has been reported in at least two studies [ 16 , 19 ]. On the other hand, while the same dosage of IVA can cause choroidal thinning, the extent was similar or lower to that of IVBr [ 20 ].…”

Section: Discussionmentioning

confidence: 55%

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment

et al. 2022

View full text Add to dashboard Cite

Background To compare the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment (PED) in age-related macular degeneration. Methods Eighty-three eyes of 83 patients diagnosed with type 1 macular neovascularization were included and retrospectively analysed using multimodal imaging. Forty-nine eyes were treated with intravitreal aflibercept injections (IVA group), and 34 eyes were treated with brolucizumab (IVBr group), with three consecutive injections administered as induction therapy. Before treatment and 1, 2, and 3 months after the first treatment, the maximum height (MH) and maximum diameter (MD) of the PED were measured using optical coherence tomography in each treatment group. Results In the IVA group, MH at baseline (228 ± 169 μm) diminished to 180 ± 150 (P = 0.2558), 165 ± 140 (P = 0.0962), and 150 ± 129 µm (P = 0.0284) at 1, 2, and 3 months after treatment, respectively; the reduction at 3 months was significant. In contrast, in the IVBr group, the MH was 307 ± 254 µm before treatment, and it decreased to 183 ± 156 µm (P = 0.0113), 139 ± 114 µm (P = 0.0003), and 125 ± 126 µm (P < 0.0001) at 1, 2, and 3 months after treatment, respectively, and the reduction at 1 month was significant. In both groups, the MD did not regress significantly. Conclusions The results suggested that the MH of PED after IVBr treatment regressed faster than that after IVA treatment.

show abstract

Section: Discussionmentioning

confidence: 55%

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since better anatomical and visual outcomes have been associated with the decrease in choroidal thickness after therapy with intravitreal aflibercept, 66 a multicenter study in Japan investigated the effect of brolucizumab on subfoveal choroidal thickness (SCT) of eyes with nAMD during the loading phase of treatment. 67 Their analysis showed remarkable SCT reduction in both treatment-naïve eyes and eyes previously treated with other anti-VEGFs. In subjects without prior treatment, greater SCT decrease was noted with intravitreal brolucizumab than that described with other anti-VEGFs, and this decrease was related to retinal fluid resolution.…”

Section: Real-world Clinical Datamentioning

confidence: 98%

Section: Real-world Clinical Datamentioning

confidence: 99%

“… No AEs were noted. Tamashiro et al 67 2022 Retrospective, multicentre 72 (73) 1. BCVA improved significantly in the treatment-naive group (p=0.003) whereas no significant change in BCVA was observed in the switch-therapy group (p= 0.404).…”

Section: Real-world Clinical Datamentioning

confidence: 99%

“…In subjects without prior treatment, greater SCT decrease was noted with intravitreal brolucizumab than that described with other anti-VEGFs, and this decrease was related to retinal fluid resolution. 67 Only one prospective study has so far explored the efficacy of brolucizumab after loading dose in nAMD patients that had not received prior treatment. 68 Its results are consistent with those reported in brolucizumab registration studies, 52 revealing improvements in visual acuity and macular thickness.…”

Section: Real-world Clinical Datamentioning

confidence: 99%

See 2 more Smart Citations

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies

Karasavvidou¹,

Tranos²,

Panos³

2022

DDDT

View full text Add to dashboard Cite

Age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion represent some of the commonest degenerative conditions that lead to severe vision impairment in the developed countries. The gold standard treatment of complications associated with these conditions is the intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents. Brolucizumab is a newly developed, humanised, single-chain fragment of a monoclonal antibody binding all VEGF-A isoforms, which was recently approved for the treatment of neovascular AMD. Intravitreal brolucizumab promises to reduce treatment burden for nAMD patients by achieving comparable therapeutic outcomes with fewer clinic visits. Promising also appears its use for the treatment of more challenging maculopathies like diabetic macular oedema (DMO). The aim of this review is to describe the special pharmacological properties of brolucizumab and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of degenerative macular disorders.

show abstract

Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study

Ueda-Consolvo

Tanigichi

Numata

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

Cited by 26 publications

References 42 publications

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies

Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study

Contact Info

Product

Resources

About